You are here

Development of a novel whole blood coagulation assay

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL077964-01
Agency Tracking Number: HL077964
Amount: $99,487.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2004
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
HEMODYNE, INC. 800 E LEIGH ST, STE 114
RICHMOND, VA 23219
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARCUS CARR
 (804) 828-6483
 MCARR@HSC.VCU.EDU
Business Contact
 DEVINDER BAWA
Phone: (240) 350-1110
Email: DEVINDER@HEMODYNE.COM
Research Institution
 VIRGINIA COMMONWEALTH UNIVERSITY
 
PO BOX 980568
RICHMOND, VA 23298
United States

 Nonprofit College or University
Abstract

The inability to adequately monitor the effects of newer, potent anticoagulants is increasingly apparent. These powerful drugs have a very narrow therapeutic window. This is especially true in high-risk populations such as those with hepatic and renal dysfunction. Conventional monitoring parameters (i.e., PT, aPTT, INR) do not adequately measure or predict efficacy or toxicity for many of these newer agents, in part because they are performed in the absence of platelets. It is now understood that platelets are a critical step in the production of the thrombin burst. We have developed a novel assay that tests platelet function during clotting of whole blood. This platelet assay determines the thrombin generation time (TGT). TGT correlates with thrombin's appearance in the clotting sample. TGT is short in disease states associated with thrombosis, is prolonged in diseases associated with bleeding, is prolonged by anticoagulants (and some antiplatelet agents), and is shortened by hemostatic agents. This raises the
possibility of that TGT might serve as a broad spectrum drug monitor. We have performed pilot
investigations that support this possibility. Most recently we demonstrated altered hemostatic function in patients with end stage renal disease (ESRD). The ex vivo response of ESRD blood to a low molecular weight heparin was also noted to differ significantly from normal. The studies outlined in this proposal build on these very encouraging results and, if our hypotheses are supported, will serve as the foundation for Phase II studies of TGT as a monitor of multiple agents. Clinicians need a simple, inexpensive assay that can quickly measure efficacy and predict risk of toxicity. We believe the TGT can serve this role, and improve the care to these special populations with coagulation disorders. This assay can allow clinicians to tailor anticoagulant therapy to achieve successful outcomes while preventing adverse bleeding events. These outcomes should result in reduced healthcare costs.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government